In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitory

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 4, 2009, Pages 1377-1385

  Lin, Tse I ^a,b   Lenz, Oliver ^a,b   Fanning, Gregory ^a,b   Verbinnen, Thierry ^a,b   Delouvroy, Frédéric ^a,b   Scholliers, Annick ^a,b   Vermeiren, Katrien ^a,b   Rosenquist, Âsa ^c   Edlund, Michael ^c   Samuelsson, Bertil ^c   Vrang, Lotta ^c   De Kock, Herman ^a,b   Wigerinck, Piet ^a,b   Raboisson, Pierre ^a,b   Simmen, Kenneth ^a,b  

^a TIBOTEC BVBA   (Belgium)

^b Tibotec Pharmaceuticals Ltd   (Belgium)

^c MEDIVIR AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5 CYCLOPROPYL 2 (4 FLUOROPHENYL) 6 [N (2 HYDROXYETHYL)METHANESULFONAMIDO] N METHYLBENZOFURAN 3 CARBOXAMIDE; NM 107; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; TMC 435350; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INTERFERON-ALPHA; MALE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; TISSUE DISTRIBUTION; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 65749112245     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01058-08     Document Type: Article

References (48)

1. Andries, K., M. Moeremans, T. Gevers, R. Willebrords, C. Sommen, J. Lacrampe, F. Janssens, and P. R. Wyde. 2003. Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antivir. Res. 60s 209-219.
2. Back, M., P.-O. Johansson, F. Wangsell, F. Thorstensson, I. Kvarnstrom, S. Ayesa, H. Wahling, M. Pelcman, K. Jansson, S. Lindstrom, H. Wallberg, B. Classon, C. Rydergard, L. Vrang, E. Hamelink, A. Hallberg, S. Rosenquist, and B. Samuelsson. 2007. Novel potent macrocyclic inhibitors of the hepa-titis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs. Bioorg. Med. Chem. 15:7184-7202.
3. Baker, S. M., L. Karlsson, and R. L. Thurmond. 2003. Cloning, expression, purification, and activity of dog (Canis familiaris) and monkey (Saimiri boliviensis) cathepsin S. Protein Expr. Purif. 28:93-101. (Pubitemid 36453183)
4. Bartenschlager, R. 2002. Hepatitis C vims replicons: potential role for drag development. Nat. Rev. Drug Discov. 1:911-916.
5. Blight, K. J., J. A. McKeating, J. Marcotrigiano, and C. M. Rice. 2003. Efficient replication of hepatitis C virus genotype la RNAs in cell culture. J. Virol. 77:3181-3190. (Pubitemid 36228102)
6. Burns, C. J., A. M. Del Vecchio, T. R. Bailey, B. A. Kulkami, T. H. Faitg, S. R. Sherk, C. W. Blackledge, D. J. Rya, T. A. Lessen, J. Swestock, Y. Deng, T. J. Nitz, J. A. Reinhardt, H. Feng, and A. K. Saha. 31 October 2003. Benzofuran compounds, compositions and methods for treatment and pro-phylaxis of hepatitis C viral infections and associated diseases. PCT patent WO2004041201.
7. Choo, Q. L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362. (Pubitemid 19117877)
8. Chou T.C., Talaly P.1977. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J. Biol. Chem. 252:6438-6442. (Pubitemid 8193791)
9. Deufilc-Burban S., Poynard T., Sulkowski M.S., Wong J. B. 2007. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J. Viral. Hepat. 14:107-115. (Pubitemid 46146705)
10. Forestier, N., H. W. Reesink, C. J. Weegink, L. McNair, T. L. Kiefer, H.-M. Chu, S. Purdy, P. L. M. Jansen, and S. Zeuzem. 2007. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46:640-648.
11. Gale M. Jr. and E. M. Foy. 2005. Evasion of intracellular host defence by hepatitis C virus. Nature 436:939-945.
12. Ghobrial R.M., Steadman R., Gornbein J., Lassman C., C. D. Holt, P. Chen, D. G. Farmer, H. Yersiz, N. Dañino, E. Collisson, A. Baquarizo, S. S. Han, S. Saab, L. I. Goldstein, J. A. Donovan, K. Esrason, and R. W. Busuttil. 2001. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann. Surg. 234:384-393. (Pubitemid 32237880)
13. Global Burden of Hepatitis C Working Group. 2004. Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol. 44:20-29.
14. Gong, E., T. Ivens, C. Van den Eynde, S. Hallenberger, and K. Hertogs. 2008. Development of antiviral assays for profiling compounds against a panel of positive-strand RNA viruses using ATP/luminescence readout. J. Virol. Methods 151:121-125.
15. Gordon, C. P., and P. A. Keller. 2005. Control of hepatitis C: a medicinal chemistry perspective. J. Med. Chem. 48:1-20. (Pubitemid 40105243)
16. Hinrichsen, H., Y. Bennamou, H. Wedemeyer, M. Reiser, R. E. Sentjens, J. L. Calleja, X. Forns, A. Erhardt, J. Cronlein, R. L. Chaves, C-L. Yong, G. Nehmiz, and G. G. Steinmann. 2004. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127:1347-1355.
17. Jochmans, D., J. Deval, B. Kesteleyn, H. Van Marck, E. Bettens, I. De Baere, P. Dehertogh, T. Ivens, M. Van Ginderen, B. Van Schoubroeck, M. Ehteshami, P. Wigerinck, M. Götte, and K. Hertogs. 2006. Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action. J. Virol. 80:12283-12292.
18. Johnson, C. L., D. M. Owen, and M. Gale, Jr. 2007. Functional and thera-peutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense. J. Biol. Chem. 282:10792-10803. (Pubitemid 47093463)
19. Korba, B. E., and J. L. Gerin. 1992. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antivir. Res. 19:55-70.
20. Kuo, G., Q. L. Choo, H. J. Alter, G. L. Gitnick, A. G. Redeker, R. H. Purcell, T. Miyamura, J. L. Dienstag, M. J. Alter, C. E. Stevens, et al. 1989. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362-364.
21. Kwo, P., E. Lawitz, J. McCone, E. Schiff, J. Vierling, D. Pound, M. Davis, J. Galati, S. Gordon, N. Ravendhran, L. Rossaro, F. Anderson, I. Jacobson, R. Rubin, P. Mukhopadhyay, E. Chaudhri, L. Pedicone, and J. Albrecht. 2008. Interim results from HCV SPRINT-I: RVR/EVR from phase 2 study of boceprevir plus pegintron (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 CHC. J. Hepatol. 48:S372.
22. Lamarre, D., P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D. R. Cameron, M. Cartier, M. G. Cordingley, A-M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagace, S. R. LaPlante, H. Natjes, M.-A. Poupart, J. Rancourt, R. E. Sentjens, R. St. George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C-L. Yong, and M. Llinas-Brunet. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
23. Lawitz, E., M. Rodriguez-Torres, A. J. Muir, T. L. Kieffer, L. McNair, A. Khunvichai, and J. G. McHutchison. 2008. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J. Hepatology 49:163-169.
24. Liang, Y., H. Ishida, O. Lenz, T.-I. Lin, O. Nyanguile, K. Simmen, R. B. Pyles, N. Bourne, M. Yi, K. Li, and S. M. Lemon. 2008. Antiviral suppression versus restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology doi: 10.1053/j.gastro.2008.07.023.
25. Lin, K., A. D. Kwong, and C Lin. 2004. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicón cells. Antimicrob. Agents Chemother. 48:4784-4792. (Pubitemid 39577685)
26. Lin, K., R. B. Perni, A. D. Kwong, and C. Lin. 2006. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicón cells. Antimicrob. Agents Chemother. 50:1813-1822.
27. Lindenbach, B. D., M. J. Evans, A. J. Syder, B. WoIk, T. L. Tellinghuisen, C C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and C M. Rice. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626.
28. Lindenbach, B. D., and C M. Rice. 2005. Unravelling hepatitis C virus replication from genome to function. Nature 436:933-938.
29. Loewe, S., and H. Muischnek. 1926. Effect of combinations: mathematical basis of problem. Arch. Exp. Pathol. Pharmakol. 114:313-326.
30. Lohmann, V., S. Hoffmann, U. Herian, F. Penin, and R. Bartenschlager. 2003. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J. Virol. 77:3007-3019. (Pubitemid 36228086)
31. Lohmann, V., F. Körner, J. Koch, U. Herian, L. Theilmann, and R. Barten-schlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
32. Manns, M. P., G. R. Foster, J. K. Rockstroh, S. Zeuzem, F. Zoulim, and M. Houghton. 2007. The way forward in HCV treatmentfinding the right path. Nat. Rev. Drug Discov. 6:991-1000.
33. Micallef, J. M., J. M. Kaldor, and G. J. Dore. 2006. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of lon-gitudinal studies. J. Viral Hepat. 13:34-41.
34. Paeshuyse, J., I. Vliegen, L. Coelmont, P. Leyssen, O. Tabarrini, P. Herd-ewijn, H. Mittendorfer, J. Easmon, V. Cecchetti, R, Bartenschlager, G. Puerstinger, and J. Neyts. 2008. Comparative in vitro anti-hepatitis C virus activity of a selected series of polymerase, protease, and helicase inhibitors. Antimicrob. Agents Chemother. 52:3433-3437.
35. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-205. (Pubitemid 20377558)
36. Raboisson, P., H. de Kock, A. Rosenquist, M. Nilsson, L. Salvador-Oden, T.-I. Lin, N. Roue, V. Ivanov, H. Wähling, K. Wickström, E. Hamelink, M. Edlund, L. Vrang, S. Vendeville, W. Van de Vreken, D. McGowan, A. Tahri, L. Hu, C. Boutton, O. Lenz, F. Delouvroy, G. Pille, D. Surleraux, P. Wiger-inck, B. Samuelsson, and K. Simmen. 2008. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of die hepatitis C virus NS3 protease leading to die discovery of TMC435350. Bioorg. Med. Chem. Lett. 18:4853-4858.
37. Reesink, H., R. Verloes, K. Abou Farha, A. Van Vliet, C. Weegink, G. van't Klooster, F. Aharchi, K. Marien, P. Van Remoortere, H. de Kock, F. Bro-eckaert, G. Fanning, P. Meyvisch, E. Van Beirendonck, and K. Simmen. 2008. Safety of the HCV protease inhibitor TM.C435350 in healthy volun-teers and safety and activity in chronic hepatitis C infected individuals: a phase I study. J. Hepatol. 48:S28-S29.
38. Reesink, H. W., S. Zeuzem, C J. Weegink, N. Forestier, A. van Vliet, J. van de Wetering de Rooij, L. McNair, S. Purdy, R. Kauffman, J. Alam, and P. L. M. Jansen. 2006. Rapid decline of virai RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131:997-1002. (Pubitemid 44498690)
39. Saito, T., and M. Gale, Jr. 2008. Regulation of innate immunity against hepatitis C virus infection. Hepatol. Res. 38:115-122.
40. Sarrazin, C, R. Rouzier, F. Wagner, N. Forestier, D. Larrey, S. K. Gupta, M. Hussain, A. Shah, D. Cutler, J. Zhang, and S. Zeuzem. 2007. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon al-pha-2b for genotype 1 nonresponders. Gastroenterology 132:1270-1278. (Pubitemid 46627577)
41. Simmonds, P. 2004. Genetic diversity and evolution of hepatitis C virus-15 years on. J. Gen. Virol. 85:3173-3188. (Pubitemid 39445434)
42. Strader, D. B., T. Wright, D. L. Thomas, L. B. Seeff, and American Associ-ation for the Study of Liver Diseases. 2004. Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147-1171.
43. Takáno, S., K. Nakamura, S. Kawai, O. Yokosuka, Y. Satomura, and M. Omata. 1996. Prospective assessment of donor blood screening for antibody to hepatitis C vims by first-and second-generation assays as a means of preventing posttransfusion hepatitis. Hepatology 23:708-712.
44. Thurmond, R. L., S. Sun, C. A. Sehon, S. M. Baker, H. Cai, Y. Gu, W. Jiang, J. P. Riley, K. N. Williams, J. P. Edwards, and L. Karlsson. 2004. Identifi-cation of a potent and selective noncovalent cathepsin S inhibitor. J. Phar-macol. Exp. Ther. 308:268-276. (Pubitemid 38090727)
45. van't Klooster, G. A. E., I. Vanwelkenhuysen, R. Hooymaijers, K. BoI, M. Voets, J. Van Houdt, R. A. L. Verloes, F. Aharchi, K. Marien, P. Van Remoortere, F. Broeckaert, H. de Kock, and K. A. Simmen. 2008. Once-daily regimens of the HCV NS3/4A-protease inhibitor TMC435350 are predicted to provide therapeutic exposure in plasma and liver. J. Hepatol. 48:S321.
46. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H.-G. Krausslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796. (Pubitemid 41021213)
47. Wölk, B., D. Sansonno, H.-G. Krausslich, F. Dammacco, C. M. Rice, H. E. Blum, and D. Moradpour. 2000. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J. Virol. 74:2293-2304.
48. Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust hepatitis C vims infection in vitro. Proc. Natl. Acad. Sei. USA 102:9294-9299. (Pubitemid 40923557)